Plain-language coverage of FDA regulatory changes, supplier and market developments, new research, and community trends that affect peptide research decisions.
News Library
Search FDA updates, supplier alerts, research developments, and community trends. Filters keep the news archive easy to scan as coverage grows.
Showing 7 of 7 updates
On April 15, 2026 the FDA moved to remove 12 peptides from its significant-safety-concerns list, effective April 22. Here's exactly what it means — and doesn't.
A source-based fact check of viral claims that 14 of 19 Category 2 peptides were unbanned, including what is official and what still appears unverified.
A plain-language breakdown of FDA's February 2026 enforcement posture on non-FDA-approved GLP-1 products and research-only labeling mismatches.
Lilly's Phase 3 TRIUMPH-1 topline data showed up to 28.3% average weight loss at 80 weeks and 30.3% in a two-year subgroup.
Key policy and market shifts affecting how researchers track availability, sourcing reliability, and quality signals.
An overview of evolving third-party testing expectations and how to interpret newer documentation patterns.
A quick look at how platform moderation and channel policy updates are changing where peptide communities share information.